ChiCTR2500103367 版本V1.0 版本创建时间2025/05/28 14:12:52 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500103367 

最近更新日期:

Date of Last Refreshed on:

2025-05-28 14:12:46 

注册时间:

Date of Registration:

2025-05-28 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

老年人支气管哮喘中医证候分布与临床特征研究

Public title:

Study on distribution and clinical characteristics of TCM syndromes of bronchial asthma in the elderly

注册题目简写:

English Acronym:

研究课题的正式科学名称:

老年人支气管哮喘中医证候分布与临床特征研究

Scientific title:

Study on distribution and clinical characteristics of TCM syndromes of bronchial asthma in the elderly

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘惠梅 

研究负责人:

吴蔚 

Applicant:

Huimei Liu 

Study leader:

Wei Wu 

申请注册联系人电话:

Applicant telephone:

+86 138 1197 9733

研究负责人电话:

Study leader's
telephone:

+86 136 5128 5699

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liuhuimei2008@126.com

研究负责人电子邮件:

Study leader's E-mail:

wjyyhxk@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区花家地街6号

研究负责人通讯地址:

北京市朝阳区花家地街6号

Applicant address:

6 Huajiadi Street, Chaoyang District, Beijing

Study leader's address:

6 Huajiadi Street, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院望京医院

Applicant's institution:

Wangjing Hospital, China Academy of Chinese Medical Sciences

研究负责人所在单位:

中国中医科学院望京医院

Affiliation of the Leader:

Wangjing Hospital, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

WJEC-KT-2023-021-P001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国中医科学院望京医学伦理委员会

Name of the ethic committee:

The Medical Ethics Committee of Wangjing Hospital, Chinese Academy of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023-07-24 00:00:00

伦理委员会联系人:

王浩

Contact Name of the ethic committee:

Hao Wang

伦理委员会联系地址:

北京市朝阳区花家地街6号

Contact Address of the ethic committee:

6 Huajiadi Street, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 84739681

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院望京医院

Primary sponsor:

Wangjing Hospital, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市朝阳区花家地街6号

Primary sponsor's address:

6 Huajiadi Street, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院

具体地址:

北京市朝阳区花家地街6号

Institution
hospital:

Wangjing Hospital, China Academy of Chinese Medical Sciences

Address:

6 Huajiadi Street, Chaoyang District, Beijing

经费或物资来源:

自筹

Source(s) of funding:

Self financing

研究疾病:

支气管哮喘  

Target disease:

Asthma

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1. 客观总结老年人哮喘的中医证候分布,以指导规范化辨证治疗,为建立针对老年 人哮喘的中医诊疗方案提供依据; 2. 采集一般资料、肺功能、炎症及免疫相关生物标志物、气道壁厚度、哮喘控制水平、生活质量等指标,总结老年人哮喘不同表型/内型的临床特征,为进一步机制探索提 供方向,并为开展个体化治疗研究奠定基础。  

Objectives of Study:

1.Objective summary of the distribution of TCM syndromes of elderly asthma, in order to guide the standardized treatment of syndrome differentiation, to provide a basis for the establishment of TCM diagnosis and treatment plan for elderly asthma; 2.Collection of general data,Lung function,Inflammatory and immune-related biomarkers,airway wall thickness, asthma control level, quality of life and other indicators were collected to summarize the clinical characteristics of different phenotypes/endotypes of asthma in the elderly, so as to provide directions for further mechanism exploration and lay a foundation for individual treatment research.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、符合老年人哮喘诊断标准,年龄>=65 岁且<100 岁,性别不限; 2、 目前处于支气管哮喘慢性持续期或临床控制期; 3、自愿参加本项目并签署知情同意书。

Inclusion criteria

1.Meets the diagnostic criteria for asthma in the elderly, aged between 65 and 100 years old, with no gender limitation; 2.Currently in the chronic or clinically controlled phase of bronchial asthma; 3.Voluntarily participate in this project and sign the informed consent form.

排除标准:

1、合并严重语言、听力障碍及精神异常等,不能正确理解及配合完成问卷调查者; 2、合并其他系统疾病控制不稳定,相关临床症状显著,可能影响四诊信息采集者。

Exclusion criteria:

1.Those who have severe language, hearing impairment and mental abnormalities, etc., and cannot correctly understand and cooperate with the completion of the questionnaire; 2.Patients with unstable disease control and significant clinical symptoms associated with other systems may affect the collection of information for the four diagnoses.

研究实施时间:

Study execute time:

From 2023-05-01 00:00:00 To 2025-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-10-16 00:00:00 To 2024-05-31 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

120

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院 

单位级别:

三级 

Institution
hospital:

Wangjing Hospital, China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

中医四诊信息

指标类型:

主要指标

Outcome:

Information on the four diagnoses of Chinese medicine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肺功能检测

指标类型:

次要指标

Outcome:

Pulmonary function test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞计数

指标类型:

次要指标

Outcome:

White blood cell count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C 反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-4

指标类型:

次要指标

Outcome:

Interleukin-4

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

干扰素-γ

指标类型:

次要指标

Outcome:

Interferon-γ

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

过敏原

指标类型:

次要指标

Outcome:

Allergens

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫球蛋白 E

指标类型:

次要指标

Outcome:

Allergens, immunoglobulin E

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

哮喘控制测试

指标类型:

次要指标

Outcome:

Asthma Control Test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

哮喘生活质量评估问卷

指标类型:

主要指标

Outcome:

Asthma Quality of Life Assessment Questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan, http://www.medresman.org.cn/login.aspx,2025/6/30

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn/login.aspx,2025/6/30

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-05-28 14:12:46